Acquisition Strategy Cubist Pharmaceuticals has a history of strategic acquisitions, such as acquiring Triusrx for $700M. This signals a potential willingness to explore partnerships or collaborations that can drive revenue growth.
Financial Stability Merck's acquisition of Cubist Pharmaceuticals for $9.5B provides a strong financial backing. Leveraging this stability, sales professionals could propose long-term contracts or high-value deals.
Competitive Industry Position Cubist Pharmaceuticals operates in a competitive industry alongside major players like Roche, Johnson & Johnson, and Pfizer. Identifying areas where Cubist offers unique value can be key to securing deals.
Employee Expertise With a significant employee base of 1001-5000, Cubist Pharmaceuticals likely has diverse expertise. Leveraging this talent pool in client interactions can demonstrate the company's capabilities and build trust.
Market Expansion Being a subsidiary of Merck & Co., Inc., Cubist Pharmaceuticals can leverage Merck's global presence for market expansion. Sales professionals should explore opportunities in new geographic regions or emerging markets.
93K
$1B
103K$1B
46K$1B
73K$1B
78K$1B
36K$1B
102K$1B
15K$1B
8.1K$1B
54K$1B| Cubist Pharmaceuticals Email Formats | Percentage |
| First.Last@cubist.com | 88% |
| FLast@cubist.com | 6% |
| First.L@cubist.com | 4% |
| First_Last@cubist.com | 2% |
Pharmaceutical ManufacturingMassachusetts, United States1001-5000 Employees
Effective January 22, 2015, Cubist Pharmaceuticals is now a wholly owned subsidiary of Merck & Co., Inc. For continued news and updates, we encourage you to follow Merck on LinkedIn at https://www.linkedin.com/company/merck to stay in touch and learn more.
Company Overview
Funding & FinancialsCubist Pharmaceuticals's revenue is in the range of $1B
Funding & FinancialsCubist Pharmaceuticals's revenue is in the range of $1B
1-888-653-2347 
support@leadiq.com